CDMO Technology Transfer: Moving Your Process to a Manufacturing Partner

Choosing a CDMO is only the beginning.

At some point, the manufacturing process has to move from the sponsor, laboratory, previous manufacturer, or development team into the CDMO's facility.

That is technology transfer.

And it is often where assumptions made during sourcing are tested for the first time.

A process that worked well in one environment may behave differently with:

• different equipment
• different scale
• different raw materials
• different analytical methods
• different operators
• different facility procedures

A good transfer therefore involves much more than handing over a batch record.

Technology transfer is the structured movement of manufacturing knowledge, processes, methods, materials, and supporting information from one organization or site to another.

In a CDMO relationship, this may involve transferring the process:

• from the sponsor to the CDMO
• from one CDMO to another
• from a development site to a GMP manufacturing site
• from clinical manufacturing to commercial manufacturing

The objective is for the receiving site to understand the process well enough to execute it consistently and appropriately.

A common mistake is treating technology transfer as something that begins after CDMO selection.

In reality, the selection process should already be testing whether the process can be transferred successfully.

During technical discussions, the sponsor should be asking:

• Does the CDMO have compatible equipment?
• Can it support the required scale?
• What process changes might be necessary?
• What information will the CDMO need?
• What development work is expected before GMP manufacturing?
• Are analytical methods ready to transfer?
• What materials or components have long lead times?

These questions can uncover major fit issues before the sponsor commits to a partner.

“Technology transfer” can mean very different things depending on the program.

One sponsor may have a mature process with detailed manufacturing instructions.

Another may have a laboratory process that still needs significant development before it can operate reliably at manufacturing scale.

The transfer scope should make clear what is being handed over and what the CDMO is expected to develop.

That may include:

• manufacturing process
• analytical methods
• formulation
• raw-material specifications
• equipment requirements
• process parameters
• sampling strategy
• in-process controls
• packaging or storage requirements

Clear boundaries reduce confusion later.

A manufacturing process contains knowledge that is not always captured perfectly in formal documentation.

The sponsor's technical team may know:

• which steps are particularly sensitive
• which parameters tend to drift
• which raw materials have caused trouble
• where yield is commonly lost
• which observations indicate a problem
• which parts of the process have not yet been fully optimized

That context can be extremely valuable to the receiving CDMO.

A successful transfer should create opportunities for technical teams to discuss the process directly rather than relying entirely on document exchange.

The receiving CDMO may not have identical equipment to the sending site.

That does not necessarily prevent a successful transfer.

It does mean the differences need to be understood.

Potential differences can involve:

• vessel size
• geometry
• mixing
• pumps
• filtration
• chromatography systems
• filling equipment
• sensors
• control systems

The technical team should determine whether those differences require process adjustments, engineering work, or additional studies.

Moving a process from one site to another often also involves changing scale.

A laboratory process may be moving into clinical manufacturing.

A clinical process may be moving into commercial-scale production.

At that point, the project may no longer be a simple one-to-one transfer.

The CDMO may need to perform:

• scale-up work
• process optimization
• engineering runs
• additional analytical work
• process characterization

The sponsor should understand this before assuming the transfer timeline will be short.

Manufacturing methods are not the only things being transferred.

Analytical methods may also need to move to the receiving site.

Sponsors should understand:

• which methods are mature
• which methods still need development
• what equipment is required
• what reference materials are needed
• whether method qualification or validation is required
• whether testing will remain outsourced

Analytical transfer can become a schedule bottleneck if it is addressed too late.

Two facilities may source materials differently.

That can affect process performance.

Sponsors should identify critical raw materials and determine whether:

• the same supplier will be used
• equivalent materials are available
• the CDMO has preferred suppliers
• additional qualification is required
• long lead times exist

The transfer package may contain documents such as:

• process descriptions
• batch records
• development reports
• analytical methods
• specifications
• raw-material information
• equipment requirements
• stability data
• process-flow diagrams

The exact package depends on the program.

The objective is not to generate the most documents possible.

It is to give the receiving team enough reliable information to understand and execute the process.

Technology transfer can become messy when no one knows who owns each action.

A transfer plan should clarify responsibilities for:

• document preparation
• method transfer
• material shipment
• equipment assessment
• process changes
• deviation management
• analytical work
• engineering runs
• project approvals

This is particularly important when several organizations are involved.

For example, a sponsor may be coordinating a drug substance CDMO, fill finish CDMO, analytical laboratory, and raw-material suppliers at the same time.

A technology-transfer timeline should account for more than the planned GMP batch.

Potential activities include:

technical assessment → documentation → materials → analytical transfer → equipment assessment → process adaptation → engineering work → GMP manufacturing

Some of these activities can happen in parallel.

Others depend on earlier milestones.

Sponsors should ask the CDMO to explain the critical path rather than providing only a target manufacturing date.

Depending on the program, an engineering or non-GMP run may allow the team to test the transferred process before executing a GMP batch.

This can help identify:

• equipment differences
• scale-related issues
• procedural gaps
• process-control problems
• operator questions

Whether an engineering run is necessary depends on the process and stage.

It should be treated as a risk-management decision rather than an automatic requirement.

Moving a process from one CDMO to another introduces an additional relationship.

The outgoing manufacturer may hold important process knowledge, documentation, materials, or analytical information.

Sponsors should plan carefully for:

• data access
• documentation transfer
• material transfer
• communication between technical teams
• intellectual property
• contractual obligations

A supplier transition can become difficult if these issues were not considered when the original agreement was signed.

Technology transfer necessarily involves sharing detailed manufacturing information.

Sponsors should ensure that appropriate confidentiality, intellectual-property, and contractual protections are in place.

The details of those protections belong with qualified legal counsel.

From an operational standpoint, the sponsor should also know:

• what information is being transferred
• who can access it
• which third parties may become involved

That is especially important when a CDMO outsources part of the work.

Transfers can struggle for very ordinary reasons.

Examples include:

• incomplete process documentation
• assumptions that were never written down
• equipment differences discovered late
• analytical methods not ready
• raw-material substitutions
• unrealistic timelines
• unclear responsibilities
• insufficient development work
• poor communication between technical teams

Most of these problems are easier to manage when identified before the first GMP batch.

If a sponsor already knows a process will be difficult to transfer, the selection criteria should reflect that.

A technically capable manufacturing facility may not be the best partner if the organization lacks the development support needed to adapt the process.

Likewise, a highly experienced development CDMO may be more valuable than a cheaper manufacturing option if the transfer still contains significant technical risk.

The right sourcing question becomes:

Which CDMO can realistically receive and execute this process?

not simply:

Which CDMO advertises the required service?

Useful questions include:

• Have you transferred similar processes before?
• Which facility would receive the process?
• What equipment differences do you expect?
• What information do you need from us?
• What development work do you expect before GMP manufacturing?
• How will analytical methods be transferred?
• Do you recommend an engineering run?
• What are the largest schedule risks?
• Who will lead the transfer technically?
• What does the sponsor need to provide and by when?

The answers give the sponsor a much clearer picture of how the relationship may work in practice.

Pharma Connect Navigator helps sponsors structure the sourcing process that comes before technology transfer.

Sponsors can define their program requirements, identify potentially relevant CDMOs and facilities, compare project fit, and investigate available information about capabilities, equipment, scale, and regulatory context.

That can help teams identify manufacturing partners whose facilities appear more compatible with the intended process before a detailed transfer plan begins.

Once a potential partner appears relevant, PCN supports structured introductions so the sponsor and CDMO can begin direct technical discussions.

PCN does not perform the technology transfer itself or replace technical project management.

It helps sponsors build a more informed shortlist before committing to that work.